Back to rankings

Cellebrite DI Ltd. (CLBT)

NEUTRAL
TechnologySoftware - InfrastructureIsrael

Fundamental

68

Price

$11.29

Market Cap

$2.84B

Part 1 · What the company is worth

Overview

Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company provides a platform of software solutions used to access, collect, review, extract, decode, decrypt, analyze, share and manage digital evidence across the investigative lifecycle for a range of investigations, such as child exploitation, homicide, anti-terror, border control, sexual crimes, organized crime, human trafficking, corporate security, and intellectual property theft, as well as financial crimes, including those involving cryptocurrency. It also offers Inseyets, digital forensics software that collects and reviews digital evidence from various digital sources when conducting legally sanctioned investigations; Guardian Forensics, an evidence management solution which enables customers to manage their digital forensics workflows, and to store, share and review digital evidence; Guardian Collaborate, a digital evidence sharing tool; and Guardian Investigate, a case management and AI-powered analytics solution. In addition, it provides Cellebrite Pathfinder, which reduces the time spent manually reviewing digital evidence and enables actionable insights into a range of crime types; Corellium Falcon for conducting mobile vulnerability research, exploit introspection, and malware analysis; and Corellium Viper for mobile application penetration testing capabilities. Further, the company offers professional services, such as training and certification services, and advanced services. It serves federal, state, and local agencies, as well as corporations and service providers. The company is headquartered in Petah Tikva, Israel.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Balance Sheet & Liquidity

Revenue

$496M

Trailing 12 months (through 3/31/2026)

Net Income

$72M

Trailing 12 months (through 3/31/2026)

Free Cash Flow

$125M

Total Equity

$538M

Total Liabilities

$23M

Current Ratio

1.62

Interest Coverage

-

Debt/EBITDA

0.30

Earnings Per Share

Revenue & Net Income

Free Cash Flow

Income Breakdown

Historical statement

Margins over time

Debt over time

How heavy the debt is

Growth grid

Growth — Revenue

Fair Value Estimation

Undervalued

Fair Value

$19.57

Current Price

$11.29

Margin of Safety

+42.3%

Fair Value Range

$12.72 - $26.42

Estimation Methods

Analyst Target:$15.36
DCF:$33.82
PE-based:$5.45
Graham Growth:$11.84
EPV:$1.86
Analyst Consensus:Strong Buy (14B / 1H / 0S)
Last Earnings Surprise:-2.57%

Valuation Metrics

P/E Ratio

49.22

ROE

12.4%

P/B Ratio

5.27

P/FCF

22.72

Gross Margin

83.0%

ROIC

3.8%

Profitability Radar

Value Creation (Economic Moat)

ROIC

3.8%

WACC

10.6%

ROIC − WACC

-6.7 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

Fundamental Analysis Criteria

Passed (13)

  • Gross Margin 83.0%
  • P/FCF 22.72
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • Current Ratio
  • Debt/EBITDA
  • ROE 15.5%
  • Revenue Growth 5Y 19.5%
  • Analyst Consensus 93% Buy
  • Earnings Surprise avg 6.8%
  • PEG Ratio 0.63
  • Earnings Quality (OCF/NI) 2.01
  • Net Margin Trend 16.5% vs -70.5%

Failed (6)

  • Price CAGR 0.81%
  • ROIC 3.8%
  • P/B Ratio 5.27
  • CapEx intensity
  • DCF valuation (Overvalued)
  • Piotroski F-Score 2/9

Unavailable (8)

  • EPS data insufficient
  • Dividend Payout NaN%
  • Operating Margin NaN%
  • Interest Coverage
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Price below Graham Number
  • Share Dilution (missing shares data)

Piotroski F-Score

2/9

Serious financial concerns

score
criteria

Earnings Quality

2.01

High quality: earnings backed by cash

Share Dilution

-

Buying back shares. Shareholder friendly

Governance

Part 2 · The price and when to enter

This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.

Latest News

Recent headlines for CLBT, sourced from Markets Gazette.

No recent news for CLBT.